BioCryst Pharmaceuticals, Inc. (BMV:BCRX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 36.92B -12.9% |
| Revenue (ttm) | 15.97B +75.9% |
| Net Income | -8.26B |
| EPS | -37.83 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 21.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,010 |
| Average Volume | 955 |
| Open | 150.40 |
| Previous Close | 159.00 |
| Day's Range | 149.57 - 150.40 |
| 52-Week Range | 118.00 - 201.00 |
| Beta | n/a |
| RSI | 44.51 |
| Earnings Date | May 6, 2026 |
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
News
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 Internati...
BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a strategy to build a diversified rare disease portfolio by 2030, leveraging ORLADEYO's growth and recent business development moves. Navenibart's pivotal data and BLA filing are expected by end of next year, while the Netherton syndrome program aims for proof-of-concept results by year-end.
BioCryst price target raised to $28 from $25 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $28 from $25 and keeps an Outperform rating on the shares. Orladeyo posted a typical seasonal Q1…
BioCryst reports Q1 EPS ($2.98), consensus 11c
Reports Q1 revenue $156.41M, consensus $151.12M. BioCryst (BCRX) recorded a GAAP operating loss of $701.6M for the first quarter, primarily reflecting the special, non-cash charge related to acquired ...
BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth year-over-year, with ORLADEYO revenues up 21% and strong U.S. demand. Guidance for 2026 is unchanged despite a pediatric manufacturing delay, and liquidity is bolstered by a new European licensing deal for navenibart.
BioCryst Pharmaceuticals Earnings release: Q1 2026
BioCryst Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
BioCryst Pharmaceuticals Slides: Q1 2026
BioCryst Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
BioCryst Pharmaceuticals Quarterly report: Q1 2026
BioCryst Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted si...
BioCryst enters navenibart license agreement with Neopharmed Gentili
BioCryst (BCRX) announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. I...
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst Pharmaceuticals Proxy statement: Proxy filing
BioCryst Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
BioCryst Pharmaceuticals Proxy statement: Proxy filing
BioCryst Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
BioCryst to Report First Quarter 2026 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on...
BioCryst price target raised to $14 from $13 at RBC Capital
RBC Capital raised the firm’s price target on BioCryst (BCRX) to $14 from $13 and keeps an Outperform rating on the shares as part of the firm’s broader research note…
BioCryst appoints Sandeep Menon as chief research and development officer
BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served as chief development officer, overseeing...
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
BioCryst reports inducement grants under Nasdaq listing rule
BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units covering an aggregate of 65,850 shar...
BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Revenue growth is driven by strong U.S. performance, expanding prescriber base, and high patient retention among super-responders. The pipeline is advancing with navenibart and a KLK5 inhibitor, while pediatric and community market penetration continues to rise.
BioCryst price target raised to $22 from $21 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on BioCryst (BCRX) to $22 from $21 and keeps an Outperform rating on the shares. While the company preannounced Q4 results…
BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered record 2025 revenue and profitability, driven by ORLADEYO growth and strategic portfolio expansion. 2026 guidance projects continued double-digit revenue growth, with new pediatric and injectable HAE therapies advancing and strong U.S. market focus.
BioCryst Pharmaceuticals Annual report: Q4 2025
BioCryst Pharmaceuticals has published its Q4 2025 annual report on February 26, 2026.
BioCryst Pharmaceuticals Earnings release: Q4 2025
BioCryst Pharmaceuticals released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.